Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment.
Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions.
Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions.
Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
Location: China, Jiangsu, Nantong
Employees: 1001-5000
Founded date: 1998
Investors 2
| Date | Name | Website |
| - | Qiming Ven... | qimingvent... |
| - | Qiming Ven... | qimingvc.c... |
Mentions in press and media 23
| Date | Title | Description |
| 09.09.2026 | First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA | BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ -- Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8... |
| 14.08.2026 | China’s Bulk-Buying Drug Program Is Helping Insulin Suppliers Break Into Western Markets | (Yicai) Aug. 14 -- China’s volume‑based drug procurement program, introduced in 2019 to reduce prices and tighten oversight, has driven domestic insulin suppliers to upgrade production facilities, strengthen quality controls, and scale up, ... |
| 12.06.2026 | Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bo... | BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity ... |
| 05.06.2026 | China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange | SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, listed on the Hong Kong Stock Exchange on June 5, 2... |
| 27.05.2026 | Domestic Display Chip Leader Viewtrix Technology Listed on Hong Kong Stock Exchange | SHANGHAI, May 27, 2026 /PRNewswire/ -- Viewtrix Technology, a portfolio company of Qiming Venture Partners and a leading display chip design enterprise in China, successfully listed on the Hong Kong Stock Exchange, marking the sixth IPO for... |
| 30.11.2025 | Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery | SHANGHAI, Nov. 30, 2025 /PRNewswire/ -- On the afternoon of November 26, a major Grade 5 fire spread across multiple residential buildings in Wang Fuk Court in Tai Po, Hong Kong, causing severe casualties and drawing widespread public conce... |
| 30.06.2025 | Qiming Venture Partners' Portfolio Company Unisound Successfully Lists on the Hong Kong Stock Exchange | SHANGHAI, June 30, 2025 /PRNewswire/ -- On June 30th, Beijing time, Unisound, a pioneer in the industrialization of AI technologies in China and a portfolio company of Qiming Venture Partners, has successfully debuted on the Hong Kong Stock... |
| 21.06.2025 | Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions | In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c redu... |
| 10.03.2025 | Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity | BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bof... |
| 18.12.2024 | Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase... | BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the... |
Show more